Why Pigmentation Comes Back After Treatment Stops
Relapse trials show melasma held stable on a sunscreen with iron-oxide visible-light protection and worsened significantly on an otherwise identical UV-only sunscreen, even after successful treatment.
Why does a spot you treated successfully sometimes reappear months later? In a lot of cases the treatment worked exactly as intended, and the relapse is not a failure of the treatment. It is what happens when the protection meant to run alongside it stops.
A trial built specifically to test relapse
A French trial followed melasma patients whose condition was already under control and randomized them to one of two otherwise similar sunscreens, one formulated with visible-light protection through iron oxide, one without, tracking them over six months through spring and summer. 1 This was not a treatment trial. Both groups had already achieved improvement before it began. The only question was whether the result would hold.
What determined whether it held
The group using the sunscreen without added visible-light protection saw a significantly larger increase in melasma severity over the six months than the group with visible-light protection. 1 Both groups were using sunscreen. Both had the same UV protection. The single variable separating a relapse from a maintained result was whether visible light was also being addressed.
The same pattern during active treatment, not just after
An earlier trial makes the same point from the treatment side rather than the maintenance side. Patients using hydroquinone alongside a visible-light-protective sunscreen improved more than patients using hydroquinone with a UV-only sunscreen, showing 15%, 28% and 4% greater improvement across the melasma severity score, colorimetric readings, and direct melanin measurement, respectively. 2 The active depigmenting ingredient was identical in both groups. The gap came entirely from whether visible light was also being blocked.
Why this pathway does not just fade on its own
Part of why relapse happens so readily without ongoing visible-light protection traces back to the mechanism itself. Blue-violet visible light triggers a tyrosinase-related protein complex in melanocytes that keeps producing pigment well after an exposure ends, a response documented as lasting up to three months after a single controlled exposure. 3 Separate research tracking repeated low-dose exposure found pigment still visibly present in dark skin eight days after the last exposure ended, alongside sustained activity in the genes, tyrosinase among them, that build melanin. 4 Every subsequent unprotected exposure is not starting from zero. It adds to a pathway already primed to respond, in skin that has already shown it will respond to this exact wavelength band.
What this means for anyone who has finished a treatment
A successful outcome from any hyperpigmentation treatment, whatever the active ingredient, is not a finished state. It is a state that has to be maintained against ongoing light exposure, and the evidence above says plainly that UV protection alone is not sufficient maintenance for a visible-light-sensitive pigment condition. When the relapse happens, it usually is not a sign the original treatment failed. It is a sign that half of the light exposure that caused the problem in the first place was never being addressed.
References
- Boukari F, Jourdan E, Fontas E, Montaudie H, Castela E, Lacour JP, Passeron T. Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial. J Am Acad Dermatol. 2015, 72(1):189-190.e1. PMID 25443629. doi.org/10.1016/j.jaad.2014.08.023
- Castanedo-Cazares JP, Hernandez-Blanco D, Carlos-Ortega B, Fuentes-Ahumada C, Torres-Alvarez B. Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial. Photodermatol Photoimmunol Photomed. 2014, 30(1):35-42. PMID 24313385. doi.org/10.1111/phpp.12086
- Duteil L, Cardot-Leccia N, Queille-Roussel C, Maubert Y, Harmelin Y, Boukari F, Ambrosetti D, Lacour JP, Passeron T. Differences in visible light-induced pigmentation according to wavelengths: a clinical and histological study in comparison with UVB exposure. Pigment Cell Melanoma Res. 2014, 27(5):822-826. PMID 24888214. doi.org/10.1111/pcmr.12273
- Kim S, Rainer BM, Qi J, Brown I, Ogurtsova A, Leung S, Garza LA, Kang S, Chien AL. Clinical and molecular change induced by repeated low-dose visible light exposure in both light-skinned and dark-skinned individuals. Photodermatol Photoimmunol Photomed. 2022, 39(3):204-212. PMID 35861041. doi.org/10.1111/phpp.12819
